Postpardum Depression Drug Breakthrough, BlackRock’s Risky Software Bet, Tiffany Earnings
March 22, 2019
43 min
Full
1,309 of 5,353
March 22, 2019
Postpardum Depression Drug Breakthrough, BlackRock’s Risky Software Bet, Tiffany Earnings
0:00 / 43:01
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Bloomberg Originals Episodes Around March 22, 2019
Episode 1,309 of 5,353 — walk the feed in the order it was published.
43:01This episodePostpardum Depression Drug Breakthrough, BlackRock’s Risky Software Bet, Tiffany Earnings
Summary
<p>Bloomberg Businessweek Editor Joel and Bloomberg News Health Care Reporter Cynthia Koons discuss the trials and tribulations of postpartum depression drug Zulresso. Annie Massa, Bloomberg News Investing Reporter, talks about BlackRock buying risky software provider eFront. Charlie Bobrinskoy, Head of Investment Group at Ariel Investments, explains why Tiffany is a good company but not awlays a good stock. Megan Bent, Founder of Harbinger Ventures, discusses the state of funding for women entrepreneurs. Matthew Wadiak, Co-Founder of Blue Apron, talks about launching Cooks Venture a next generation food company saving the planet one chicken at a time. And we Drive to the Close with Charles Lemonides, Chief Investment Officer at ValueWorks. </p><p>Hosts: Carol Massar and Jason Kelly. Producer: Paul Brennan </p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.